Joshua Cohen

Senior Contributor|Healthcare

I'm an independent healthcare analyst with more than 24 years of experience analyzing healthcare and pharmaceuticals. Specifically, I analyze the value (costs and benefits) of biologics and pharmaceuticals, patient access to prescription drugs, the regulatory framework for drug

article image
114 views9 hours ago

Biden Administration Says It Plans To Use March-In-Rights For Drugs To Lower Prices

Use of march-in-rights depends on government's interpretation of whether an original patent holder has made products available to the public on “reasonable terms.”

article image
200 viewsDec 5, 2023

Congress Wants To Include List Prices Of Drugs In DTC Ads: Will It Matter?

A bill in the Senate would require pharmaceutical manufacturers to include list prices of prescription drugs in direct-to-consumer ads on television and online.

article image
3,452 viewsDec 4, 2023

Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System

Impediments to biosimilar access prevent market competition from working properly, raise patient cost-sharing and harm long-term sustainability of biosimilar development.

article image
585 viewsDec 2, 2023

Europe And U.S. Diverge Sharply On Treatment Of Gender Incongruence In Minors

In line with precautionary principle, introduction of treatments whose effects are either disputed or unknown should be carefully reviewed before being routinely adopted.

article image
579 viewsDec 2, 2023

Without RCT, FDA May Consider Approval Of A Cross-Sex Hormone For Gender-Affirming Care

The FDA may consider approval of the cross-sex hormone estradiol for gender incongruence in adults and minors based on an observational study and not an RCT with placebo.